ALKERMES | Omløpsmidler



Current Assets Endring Dato
AbbVie USD 25.58B 2.2B 2024-12
Acadia Pharmaceuticals USD 938.32M 150.03M 2024-12
ALKERMES USD 1.42B 167.74M 2024-12
Amgen USD 29.03B 2.26B 2024-12
Biogen USD 7.46B 626.3M 2024-12
BioMarin Pharmaceutical USD 3.23B 175.84M 2024-12
Bristol-Myers Squibb USD 29.78B 1.7B 2024-12
Eli Lilly USD 32.74B 1.32B 2024-12
Gilead Sciences USD 19.17B 4.39B 2024-12
Ionis Pharmaceuticals USD 2.62B 93.56M 2024-12
J&J USD 55.89B 2.64B 2024-12
Malin Corporation EUR 35.9M 100K 2024-06
Merck USD 38.78B 1.58B 2024-12
Neurocrine Biosciences USD 1.72B 151.9M 2024-12
Otsuka Holdings JPY 1.37T 67.88B 2024-12
Pfizer USD 50.36B 7.14B 2024-12
Regeneron Pharmaceuticals USD 27.21B 7.88B 2024-12
Vertex Pharmaceuticals USD 9.6B 207.7M 2024-12



ALKERMES Omløpsmidler - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Apr 2025.